148 related articles for article (PubMed ID: 18363671)
1. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.
Ward CL; Dev A; Rigby S; Symonds WT; Patel K; Zekry A; Pawlotsky JM; McHutchison JG
J Viral Hepat; 2008 Aug; 15(8):571-7. PubMed ID: 18363671
[TBL] [Abstract][Full Text] [Related]
2. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
4. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
Ullah S; Rehman HU; Idrees M
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
[TBL] [Abstract][Full Text] [Related]
6. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
Sarrazin C; Berg T; Lee JH; Teuber G; Dietrich CF; Roth WK; Zeuzem S
J Hepatol; 1999 Jun; 30(6):1004-13. PubMed ID: 10406177
[TBL] [Abstract][Full Text] [Related]
7. Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.
Castilho MC; Martins AN; Horbach IS; Perez Rde M; Figueiredo FA; Pinto Pde T; Nabuco LC; Lima DB; Tanuri A; Porto LC; Ferreira Júnior Oda C
Mem Inst Oswaldo Cruz; 2011 Dec; 106(8):968-75. PubMed ID: 22241118
[TBL] [Abstract][Full Text] [Related]
8. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
[TBL] [Abstract][Full Text] [Related]
9. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
Mejer N; Fahnøe U; Galli A; Ramirez S; Weiland O; Benfield T; Bukh J
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928732
[TBL] [Abstract][Full Text] [Related]
10. Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
Nakamura M; Saito H; Ikeda M; Tada S; Kumagai N; Kato N; Shimotohno K; Hibi T
J Med Virol; 2008 Apr; 80(4):632-9. PubMed ID: 18297719
[TBL] [Abstract][Full Text] [Related]
11. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy.
Hofmann WP; Polta A; Herrmann E; Mihm U; Kronenberger B; Sonntag T; Lohmann V; Schönberger B; Zeuzem S; Sarrazin C
Gastroenterology; 2007 Mar; 132(3):921-30. PubMed ID: 17383421
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
[TBL] [Abstract][Full Text] [Related]
13. Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.
Cuevas JM; Torres-Puente M; Jiménez-Hernández N; Bracho MA; García-Robles I; Carnicer F; Olmo JD; Ortega E; Moya A; González-Candelas F
J Viral Hepat; 2008 Aug; 15(8):578-90. PubMed ID: 18466261
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM
Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023
[TBL] [Abstract][Full Text] [Related]
15. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
[TBL] [Abstract][Full Text] [Related]
16. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
[TBL] [Abstract][Full Text] [Related]
17. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
[TBL] [Abstract][Full Text] [Related]
18. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
19. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]